4th May 2011 07:01
4 May 2011
LSE: VER
ANNUAL INFORMATION UPDATE 2011
Vernalis plc (LSE: VER) announces, in accordance with the requirements of Prospectus Rule 5.2, and following publication of the Company's Annual Report on 12 April 2011, that the following summarises the information and documents published or made available to the public by the Company between 27 April 2010 and 4 May 2011 inclusive.
This Annual Information Update is also being made available on the Investors section of the Company's website at www.vernalis.com.
The information referred to in this Annual Information Update was correct at the time it was published but it is acknowledged that such disclosure may, at any time, become out-of-date due to changing circumstances.
1. Announcements made via a Regulatory Information Service ("RIS")
All the documents listed below were published via a RIS on or around the dates indicated.
Date | Description of Contents of Announcement |
27/04/2010 | Annual Information Update |
27/04/2010 | AGM + Annual Report Notice |
04/05/2010 | Vernalis and Servier extend Oncology Collaboration |
19/05/2010 | Interim Management Statement |
01/06/2010 | AGM Statement |
01/06/2010 | Director/PDMR Shareholding |
03/06/2010 | Holding(s) in Company |
07/06/2010 | Holding(s) in Company |
09/06/2010 | Holding(s) in Company |
16/07/2010 | Pipeline Update |
20/07/2010 | Notice of Interim Results |
29/07/2010 | Interim Results for Six Months Ended 30 June 2010 |
06/10/2010 | Vernalis and Servier Achieve Research Milestone |
18/11/2010 | Vernalis Announces V3381 Programme Update |
18/11/2010 | Interim Management Statement |
16/12/2010 | Vernalis and H. Lundbeck A/S enter Collaboration |
21/12/2010 | Holding(s) in Company |
28/01/2011 | Holding(s) in Company |
14/03/2011 | Americas Licensing Deal for tosedostat |
16/03/2011 | Vernalis Initiates Phase I Trial of V158866 |
08/04/2011 | Notice of Results |
12/04/2011 | Announcement of Results for the Year Ended 31 December 2010 and Annual Report Notice |
12/04/2011 | Vernalis Regains A2A Receptor Antagonist Programme |
20/04/2011 | Holding(s) in Company |
04/05/2011 | AGM Notice |
All of the above UK regulatory announcements have been published via a RIS and can be obtained from the London Stock Exchange's website at www.londonstockexchange.com or the Company's website at www.vernalis.com.
2. Documents filed at Companies House
All the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated.
Date | Document Type |
20/05/2010 | Annual Report and Accounts |
01/06/2010 | Annual General Meeting Resolutions |
01/06/2010 | New Articles of Association |
12/08/2010 | CH01 - Change of Director's Details |
12/08/2010 | AR01 - Annual Return |
02/12/2010 | TM02 - Termination of Appointment of Secretary |
02/12/2010 | AP03 - Appointment of Secretary |
Copies of the above documents, filed with the Registrar of Companies, can be obtained through the Companies House website at www.companieshouse.gov.uk, or can be obtained from Companies House, Crown Way, Maindy, Cardiff, CF14 3UZ.
3. Documents published or sent to Shareholders or filed with the UK Listing Authority or submitted to the FSA
All the documents below were sent to shareholders and/or submitted to the FSA/UKLA on or around the dates indicated.
Date | Document |
01/06/2010 | Annual General Meeting Resolutions |
12/04/2011 | Annual Report and Accounts and Results Announcement |
04/05/2011 | Notice of Annual General Meeting and Form of Proxy |
Certain documents submitted to the FSA can be viewed online at the National Storage Mechanism (NSM) at www.hemscott.com/nsm.do.
The Notice of Annual General Meeting and Annual, Interim and Preliminary Reports are also available via the Investors section of the Company's website at www.vernalis.com.
4. Further Information
Further information about Vernalis plc can be found on the Company's website at www.vernalis.com.
Enquiries:
Vernalis | +44 (0) 118 989 9360 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles Justine McIlroy
| |
Taylor Rafferty | +44 (0) 20 7614 2900 |
Rob NewmanFaisal Kanth
|
Notes to Editors
About Vernalis
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
Related Shares:
Vernalis PLC